EA036658B1 - Антитела к il-25 и их применения - Google Patents

Антитела к il-25 и их применения Download PDF

Info

Publication number
EA036658B1
EA036658B1 EA201790441A EA201790441A EA036658B1 EA 036658 B1 EA036658 B1 EA 036658B1 EA 201790441 A EA201790441 A EA 201790441A EA 201790441 A EA201790441 A EA 201790441A EA 036658 B1 EA036658 B1 EA 036658B1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
antigen
binding fragment
amino acid
antibodies
Prior art date
Application number
EA201790441A
Other languages
English (en)
Russian (ru)
Other versions
EA201790441A1 (ru
Inventor
Джеми М. Оренго
Джинни Эллинн
Original Assignee
Регенерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54207847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA036658(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Регенерон Фармасьютикалз, Инк. filed Critical Регенерон Фармасьютикалз, Инк.
Publication of EA201790441A1 publication Critical patent/EA201790441A1/ru
Publication of EA036658B1 publication Critical patent/EA036658B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
EA201790441A 2014-09-23 2015-09-22 Антитела к il-25 и их применения EA036658B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462054167P 2014-09-23 2014-09-23
PCT/US2015/051407 WO2016049000A2 (en) 2014-09-23 2015-09-22 Anti-il-25 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
EA201790441A1 EA201790441A1 (ru) 2017-08-31
EA036658B1 true EA036658B1 (ru) 2020-12-04

Family

ID=54207847

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790441A EA036658B1 (ru) 2014-09-23 2015-09-22 Антитела к il-25 и их применения

Country Status (18)

Country Link
US (3) US9840557B2 (enExample)
EP (1) EP3197914B1 (enExample)
JP (2) JP6694877B2 (enExample)
KR (1) KR102576368B1 (enExample)
CN (1) CN107207589B (enExample)
AU (1) AU2015321517B2 (enExample)
CA (1) CA2961517C (enExample)
CL (2) CL2017000703A1 (enExample)
CO (1) CO2017003072A2 (enExample)
EA (1) EA036658B1 (enExample)
IL (1) IL251001B (enExample)
MA (1) MA40106A1 (enExample)
MX (1) MX2017003841A (enExample)
MY (1) MY185832A (enExample)
PH (1) PH12017500403A1 (enExample)
SG (2) SG11201701712WA (enExample)
WO (1) WO2016049000A2 (enExample)
ZA (1) ZA201701663B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4511634A4 (en) * 2022-04-18 2026-03-25 Access Medical Systems Ltd ENZYMATIC AMPLIFICATION HIGH SENSITIVITY BIOLAYER INTERFEROMETRY

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840557B2 (en) 2014-09-23 2017-12-12 Regeneron Pharmaceuticals, Inc. Anti-IL-25 antibodies and uses thereof
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
US11285191B2 (en) 2016-07-26 2022-03-29 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Immunostimulatory compositions and uses therefor
CN107213463A (zh) * 2017-05-24 2017-09-29 清华大学 白介素25在银屑病的发育中的作用
DE102017215154A1 (de) 2017-08-30 2019-02-28 Markus Bläss Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen
AU2018450414B2 (en) * 2018-11-19 2025-10-16 Beijing Kanova Biopharmaceutical Co., Ltd. Anti-IL-25 antibodies and use thereof
PH12022551471A1 (en) 2019-12-20 2023-04-24 Momenta Pharmaceuticals Inc Antibodies against integrin alpha 11 beta 1
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US11945872B2 (en) * 2020-02-11 2024-04-02 Regeneron Pharmaceuticals, Inc. Anti-ACVR1 antibodies and uses thereof
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
TW202241928A (zh) * 2021-01-08 2022-11-01 美商１０Ｘ基因組學有限公司 對冠狀病毒具有特異性的抗原結合多肽及其用途
WO2023060144A1 (en) * 2021-10-05 2023-04-13 Lanier Biotherapeutics Monoclonal antibodies to il-25 and uses thereof
CN119183384A (zh) * 2022-02-24 2024-12-24 中国抗体制药有限公司 针对警报素的双特异性结合蛋白及其用途
CN116024212B (zh) * 2022-07-29 2026-05-26 硅羿科技（上海）有限公司 抑制IL-25基因表达的siRNA及其应用
EP4687978A1 (en) * 2023-03-31 2026-02-11 NovaRock Biotherapeutics, Ltd. Anti-il-25 antibodies and methods of use thereof
WO2026067830A1 (zh) * 2024-09-30 2026-04-02 深圳市小分子新药创新中心有限公司 抗il-25单域抗体及其衍生物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008129263A1 (en) * 2007-04-18 2008-10-30 Medical Research Council Antibodies against il-25
WO2011123507A1 (en) * 2010-03-30 2011-10-06 Centocor Ortho Biotech Inc. Humanized il-25 antibodies
WO2013186236A1 (en) * 2012-06-12 2013-12-19 Orega Biotech Antagonists of il-17 isoforms and their uses
US8658169B2 (en) * 2008-09-30 2014-02-25 Medical Research Council Antibodies against IL-25

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US7060802B1 (en) * 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
WO2012097126A2 (en) * 2011-01-13 2012-07-19 The University Of Maryland, Baltimore Il-25 treatment of obesity and metabolic disorders
US9840557B2 (en) 2014-09-23 2017-12-12 Regeneron Pharmaceuticals, Inc. Anti-IL-25 antibodies and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008129263A1 (en) * 2007-04-18 2008-10-30 Medical Research Council Antibodies against il-25
US8658169B2 (en) * 2008-09-30 2014-02-25 Medical Research Council Antibodies against IL-25
WO2011123507A1 (en) * 2010-03-30 2011-10-06 Centocor Ortho Biotech Inc. Humanized il-25 antibodies
WO2013186236A1 (en) * 2012-06-12 2013-12-19 Orega Biotech Antagonists of il-17 isoforms and their uses

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANA CAMELO, JILLIAN L. BARLOW, LESLEY F. DRYNAN, DANIEL R. NEILL, SARAH J. BALLANTYNE, SEE HENG WONG, RICHARD PANNELL, WEI GAO, KE: "Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13", JOURNAL OF GASTROENTERLOGY, SPRINGER JAPAN KK, JP, vol. 47, no. 11, 1 November 2012 (2012-11-01), JP, pages 1198 - 1211, XP055222599, ISSN: 0944-1174, DOI: 10.1007/s00535-012-0591-2 *
BALLANTYNE Sarah J. et al.: Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. Journal Allergy Clinical Immunology, 2007, Vol. 120, no. 6, 1324-1331, особенно с 1327-1329 *
HARDING FIONA A; STICKLER MARCIA M; RAZO JENNIFER; DUBRIDGE ROBERT B: "The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions", MABS, LANDES BIOSCIENCE, US, vol. 2, no. 3, 1 May 2010 (2010-05-01), US, pages 256 - 265, XP009137415, ISSN: 1942-0870, DOI: 10.4161/mabs.2.3.11641 *
IGAWA TOMOYUKI; TSUNODA HIROYUKI; KURAMOCHI TAICHI; SAMPEI ZENJIRO; ISHII SHINYA; HATTORI KUNIHIRO: "Engineering the variable region of therapeutic IgG antibodies.", MABS, LANDES BIOSCIENCE, US, vol. 3, no. 3, 1 May 2011 (2011-05-01), US, pages 243 - 252, XP009153597, ISSN: 1942-0870 *
S WANG: "Advances in the production of human monoclonal antibodies | ANTI", ANTIBODY TECHNOLOGY JOURNAL, vol. 1, 29 June 2011 (2011-06-29), XP055223100 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4511634A4 (en) * 2022-04-18 2026-03-25 Access Medical Systems Ltd ENZYMATIC AMPLIFICATION HIGH SENSITIVITY BIOLAYER INTERFEROMETRY

Also Published As

Publication number Publication date
MY185832A (en) 2021-06-11
SG10201913084PA (en) 2020-03-30
CN107207589A (zh) 2017-09-26
IL251001B (en) 2021-04-29
US10640558B2 (en) 2020-05-05
US20200262912A1 (en) 2020-08-20
US9840557B2 (en) 2017-12-12
JP6916319B2 (ja) 2021-08-11
ZA201701663B (en) 2023-04-26
EP3197914B1 (en) 2024-02-07
US20180057583A1 (en) 2018-03-01
CA2961517A1 (en) 2016-03-31
US11542326B2 (en) 2023-01-03
MX2017003841A (es) 2018-02-23
AU2015321517B2 (en) 2021-02-18
WO2016049000A2 (en) 2016-03-31
BR112017005692A2 (pt) 2017-12-12
JP2020075926A (ja) 2020-05-21
AU2015321517A1 (en) 2017-04-06
CL2017000703A1 (es) 2017-12-29
NZ730105A (en) 2024-01-26
CO2017003072A2 (es) 2017-06-30
CN107207589B (zh) 2021-04-06
IL251001A0 (en) 2017-04-30
WO2016049000A3 (en) 2016-05-06
MA40106A1 (fr) 2018-06-29
JP6694877B2 (ja) 2020-05-20
PH12017500403A1 (en) 2017-07-17
CL2018003608A1 (es) 2019-03-15
KR20170063671A (ko) 2017-06-08
US20160083466A1 (en) 2016-03-24
SG11201701712WA (en) 2017-04-27
JP2017533888A (ja) 2017-11-16
CA2961517C (en) 2023-05-02
EA201790441A1 (ru) 2017-08-31
EP3197914A2 (en) 2017-08-02
KR102576368B1 (ko) 2023-09-08

Similar Documents

Publication Publication Date Title
US11542326B2 (en) Anti-IL-25 antibodies and uses thereof
US12037388B2 (en) Anti-IL-33 antibodies and uses thereof
HK40114832A (en) Anti-il-33 antibodies and uses thereof
HK40032431B (en) Anti-il-33 antibodies and uses thereof
HK40032431A (en) Anti-il-33 antibodies and uses thereof
HK1235410B (en) Anti-il-25 antibodies and uses thereof
HK1235410A1 (en) Anti-il-25 antibodies and uses thereof
BR112017005692B1 (pt) Anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica
BR112015020470B1 (pt) Anticorpo monoclonal humano isolado anti-il-33 ou fragmento de ligação ao antígeno do mesmo, seus usos, molécula de ácido nucleico isolada, vetor de expressão, e composição farmacêutica
NZ710831B2 (en) Anti-il-33 antibodies and uses thereof
HK1220467B (en) Anti-il-33 antibodies and uses thereof